| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-08-0380 |
| P8608 | Fatcat ID | release_m2uggeqvurhafh5s5l76gnq5vi |
| P698 | PubMed publication ID | 18632642 |
| P5875 | ResearchGate publication ID | 51407226 |
| P2093 | author name string | Howard M Stern | |
| Mark X Sliwkowski | |||
| Lisa Crocker | |||
| Klaus P Hoeflich | |||
| Xander Munroe | |||
| Thinh Pham | |||
| Evelyn Yao | |||
| Si Tuen Lee-Hoeflich | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| P304 | page(s) | 5878-5887 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy | |
| P478 | volume | 68 |
| Q36359705 | A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers |
| Q47158524 | A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer |
| Q35682599 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. |
| Q35041481 | A global microRNA screen identifies regulators of the ErbB receptor signaling network |
| Q26824462 | A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy |
| Q44114723 | A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. |
| Q38824661 | Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling |
| Q36223407 | Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy |
| Q55379622 | Activating HER3 mutations in breast cancer. |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q41621146 | Advances in Targeting HER3 as an Anticancer Therapy |
| Q50084900 | Advances in the management of HER2-positive early breast cancer |
| Q39863683 | Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations |
| Q27679463 | An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin |
| Q39493859 | An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. |
| Q24302462 | An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells |
| Q38876644 | Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib |
| Q38818614 | Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells |
| Q38214511 | Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer |
| Q37247862 | Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors |
| Q50909910 | Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. |
| Q54286036 | Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. |
| Q35068522 | Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics. |
| Q24602679 | Breast Cancer in the Personal Genomics Era |
| Q33728102 | CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient |
| Q37496847 | Canine pulmonary adenocarcinoma tyrosine kinase receptor expression and phosphorylation |
| Q34475414 | Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. |
| Q36562299 | Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib |
| Q83974098 | Chemotherapy-resistant metastatic breast cancer |
| Q34545157 | Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network |
| Q38109808 | Circulating tumour cells and cell-free DNA as tools for managing breast cancer |
| Q58112887 | Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer |
| Q33739262 | Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion |
| Q37215964 | Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers |
| Q38948791 | Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer. |
| Q57470658 | Combined blockade of activating mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer |
| Q35409548 | Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies |
| Q35742383 | Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer |
| Q84302634 | Comparative study on overexpression of HER2/neu and HER3 in gastric cancer |
| Q37330128 | Current approaches and future directions in the treatment of HER2-positive breast cancer |
| Q35164938 | Current neoadjuvant treatment options for HER2-positive breast cancer |
| Q38563592 | De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer. |
| Q35693389 | Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer |
| Q35999582 | Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. |
| Q36171074 | Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells |
| Q50049638 | Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. |
| Q57484390 | Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer |
| Q24293331 | Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain |
| Q64073566 | Development of Effective Therapeutics Targeting HER3 for Cancer Treatment |
| Q35889621 | Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation |
| Q37134449 | Discovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer |
| Q42370484 | Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells |
| Q33973172 | Dual HER2-targeting without chemotherapy and estrogen deprivation in the neoadjuvant setting |
| Q24615472 | Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of Medulloblastoma |
| Q36585794 | Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function |
| Q34349106 | E3 ubiquitin ligases in ErbB receptor quantity control |
| Q34348232 | EGFR signaling in breast cancer: bad to the bone. |
| Q49887890 | EGFR-TKIs resistance via EGFR-independent signaling pathways |
| Q34356008 | EGFs and ERBBs—Brief history and prospects |
| Q35558898 | ERBB receptors in cancer: signaling from the inside |
| Q33601653 | ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics |
| Q39206148 | ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells |
| Q36619622 | Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin |
| Q28283239 | Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin |
| Q90291164 | Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras |
| Q37893414 | Emerging antibody combinations in oncology |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q37992693 | Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies |
| Q37698914 | Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells |
| Q37517706 | Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor |
| Q35479646 | ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis |
| Q37200831 | ErbB3 downregulation enhances luminal breast tumor response to antiestrogens |
| Q54276976 | ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. |
| Q37643985 | Evolving novel anti-HER2 strategies |
| Q35771539 | Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells |
| Q34745805 | Expression of NRG1 and its receptors in human bladder cancer |
| Q40514315 | Expression, purification, crystallization and preliminary X-ray analysis of the HER3-9E12 Fab complex |
| Q35779022 | Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors |
| Q39177415 | Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells |
| Q54538020 | Further progress in HER2-directed therapy. |
| Q47309551 | Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing |
| Q92803851 | Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell Carcinoma |
| Q38307398 | Going for broke: targeting the human cancer pseudokinome |
| Q39687743 | H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3 |
| Q37599574 | HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma |
| Q37601863 | HER-3 expression in HER-2-amplified breast carcinoma. |
| Q35201923 | HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells |
| Q88669731 | HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3 |
| Q28237833 | HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer |
| Q38847720 | HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts |
| Q41767530 | HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. |
| Q27026178 | HER2 as a therapeutic target in head and neck squamous cell carcinoma |
| Q53691004 | HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
| Q28476604 | HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer |
| Q36511804 | HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling |
| Q34974436 | HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies |
| Q38301236 | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer |
| Q34499609 | HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development |
| Q38760738 | HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models |
| Q38725101 | HER3 as a Therapeutic Target in Cancer |
| Q27853067 | HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models |
| Q39368710 | HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy |
| Q36957145 | HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. |
| Q37778843 | HER3 mRNA as a predictive biomarker in anticancer therapy |
| Q53142393 | HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. |
| Q54478596 | HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. |
| Q64899982 | HER3 signaling and targeted therapy in cancer. |
| Q37044197 | HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells |
| Q50949577 | HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. |
| Q37136419 | HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer |
| Q38615197 | HER3/ErbB3, an emerging cancer therapeutic target |
| Q35551911 | Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. |
| Q34128962 | High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer |
| Q49834557 | Homo- and Heterodimerization of Proteins in Cell Signaling: Inhibition and Drug Design. |
| Q53799129 | Human epidermal growth factor receptor 3 in head and neck squamous cell carcinomas. |
| Q39367513 | Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk |
| Q37439397 | IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K/AKT-pathway hyperactivation |
| Q35168105 | Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities |
| Q33720335 | Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth |
| Q89219437 | Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis |
| Q35918911 | Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells |
| Q37580198 | Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF. |
| Q64879805 | Inhibition of DUSP6 sensitizes ovarian cancer cells to chemotherapeutic agents via regulation of ERK signaling response genes. |
| Q36238299 | Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration |
| Q37456176 | Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells |
| Q36610755 | Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic |
| Q47554862 | Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance |
| Q38430594 | Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity |
| Q38385463 | Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance |
| Q35599781 | Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer. |
| Q39207741 | Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies |
| Q44666075 | Interaction of Necl-4/CADM4 with ErbB3 and integrin α6 β4 and inhibition of ErbB2/ErbB3 signaling and hemidesmosome disassembly |
| Q27315979 | Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk |
| Q36088788 | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications |
| Q31134061 | Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue |
| Q43070165 | Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA. |
| Q42025768 | Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q54218749 | Lessons from breast cancer trials of HER2-kinase inhibitors. |
| Q90724348 | Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation |
| Q24321567 | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 |
| Q99711694 | Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review |
| Q39371209 | Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human cancer cells |
| Q35977527 | Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer |
| Q35624814 | Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance |
| Q37786355 | Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer |
| Q38427102 | Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man. |
| Q53078543 | Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. |
| Q31129446 | Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3 |
| Q35684440 | Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer |
| Q36440214 | Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer |
| Q64921722 | Molecular docking analysis of Cianidanol fromGinkgo biloba with HER2+ breast cancer target. |
| Q38187398 | Molecular pathways: HER3 targeted therapy |
| Q37660907 | Molecular predictors of response to trastuzumab and lapatinib in breast cancer. |
| Q39740378 | Multichromatic phenotyping of HER receptor coexpression in breast tumor tissue samples using flow cytometry--possibilities and limitations |
| Q38627347 | Multifunctional receptor-targeting antibodies for cancer therapy |
| Q36914142 | Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer |
| Q39333848 | Neratinib for the treatment of breast cancer |
| Q37381579 | Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer |
| Q36485355 | Neuregulin 1-HER axis as a key mediator of hyperglycemic memory effects in breast cancer |
| Q39605952 | Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma |
| Q37144315 | New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available |
| Q38591976 | Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer. |
| Q36356248 | Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells |
| Q35533514 | Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer |
| Q37523202 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. |
| Q83425412 | Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer |
| Q55010019 | Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies. |
| Q24293022 | Oncogenic ERBB3 mutations in human cancers |
| Q42324659 | Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling |
| Q38740481 | Overcoming resistance to HER2 inhibitors through state-specific kinase binding |
| Q38017732 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. |
| Q37444430 | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. |
| Q28081992 | PI3K mutations in breast cancer: prognostic and therapeutic implications |
| Q35562967 | PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q34664129 | Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer |
| Q37241496 | Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies |
| Q39701009 | Pertuzumab and trastuzumab: the rationale way to synergy |
| Q38219674 | Pertuzumab for the treatment of breast cancer |
| Q33618685 | Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q33680109 | Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations |
| Q91706604 | Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy |
| Q27851691 | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer |
| Q38373931 | Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer |
| Q38132047 | Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer |
| Q37982433 | Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer |
| Q38036549 | Pertuzumab: new hope for patients with HER2-positive breast cancer |
| Q92364940 | Phage display screening of therapeutic peptide for cancer targeting and therapy |
| Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
| Q35803226 | Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance |
| Q34514043 | Pharmacological targeting of the pseudokinase Her3 |
| Q33597447 | Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer |
| Q42595256 | Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. |
| Q35479665 | Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. |
| Q37173925 | Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines |
| Q58793646 | Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers |
| Q34121278 | Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors |
| Q39448675 | Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers |
| Q35558909 | Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer |
| Q35193391 | Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody |
| Q35145369 | Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma |
| Q37360194 | Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer |
| Q34735615 | Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology |
| Q30997919 | Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins |
| Q37468304 | Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors |
| Q57109788 | Progress in targeted therapy for breast cancer |
| Q35559032 | Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action |
| Q38703402 | Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance |
| Q91130415 | Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16) |
| Q30419961 | Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice |
| Q27024334 | Regulation of ERBB3/HER3 signaling in cancer |
| Q41037554 | Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer |
| Q34532338 | Reorienting the Fab domains of trastuzumab results in potent HER2 activators |
| Q34551761 | Resiliency and vulnerability in the HER2-HER3 tumorigenic driver |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q36318226 | Resistance to Trastuzumab in Breast Cancer. |
| Q35687465 | Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer |
| Q27002386 | Role of pertuzumab in the treatment of HER2-positive breast cancer |
| Q40153403 | Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. |
| Q38857859 | Sensitization of HER2 Positive Breast Cancer Cells to Lapatinib Using Plants-Derived Isothiocyanates |
| Q37353645 | Sex hormone receptor repertoire in breast cancer |
| Q39832060 | Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2. |
| Q91721637 | Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers |
| Q89286727 | Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging |
| Q38151570 | Somatic alterations as the basis for resistance to targeted therapies |
| Q33564297 | Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells |
| Q37721805 | Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. |
| Q50152287 | Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer |
| Q42117094 | Synthesis of [18F]BODIPY: bifunctional reporter for hybrid optical/positron emission tomography imaging |
| Q42109090 | Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. |
| Q52676608 | Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer. |
| Q55071512 | Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. |
| Q39931512 | Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro |
| Q38364887 | Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. |
| Q49579954 | Targeting HER2 by Combination Therapies. |
| Q35890128 | Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum |
| Q38929801 | Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. |
| Q34036131 | Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation |
| Q24312457 | Targeting androgen receptor in estrogen receptor-negative breast cancer |
| Q58796351 | Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells |
| Q26864668 | Targeting of erbB3 receptor to overcome resistance in cancer treatment |
| Q64064458 | Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer |
| Q46087491 | Targeting protein quality control pathways in breast cancer |
| Q37565022 | Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells |
| Q60960066 | Teneurins: An Integrative Molecular, Functional, and Biomedical Overview of Their Role in Cancer |
| Q91029964 | Tetraspanin CD151 impairs heterodimerization of ErbB2/ErbB3 in breast cancer cells |
| Q54498075 | The ERBB network: at last, cancer therapy meets systems biology. |
| Q36780754 | The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression |
| Q24613186 | The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis |
| Q38890318 | The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness |
| Q37312071 | The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells |
| Q38766447 | The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation |
| Q33786779 | The cooperation between hMena overexpression and HER2 signalling in breast cancer |
| Q39409348 | The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. |
| Q39028181 | The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer |
| Q34349389 | The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics |
| Q38214802 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic |
| Q37690272 | Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. |
| Q50854840 | Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance. |
| Q34720797 | Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase |
| Q27851975 | Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors |
| Q36036437 | Trastuzumab: updated mechanisms of action and resistance in breast cancer |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
| Q36629452 | Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo |
| Q35895143 | Two dimensions in targeting HER2. |
| Q37567784 | Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review). |
| Q37124053 | WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling |
| Q26825780 | What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway |
| Q35764392 | Will PI3K pathway inhibitors be effective as single agents in patients with cancer? |
| Q51128557 | [ErbB2 diagnostics in breast cancer--an update]. |
| Q54266767 | [The HER3/ERBB3 receptor: the dark side of the ERBB planet]. |
| Q35113386 | miRNA - Therapeutic tool in breast cancer? Where are we now? |
| Q41592800 | siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells |
Search more.